DK3235824T3 - Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat - Google Patents

Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat Download PDF

Info

Publication number: DK3235824T3
Authority: DK; Denmark
Prior art keywords: gemcitabin; alaninyl; benzyloxy; phenyl; phosphate
Prior art date: 2012-11-16

Application number

DK17169878.0T

Other languages

English (en)

Inventor

Christopher Mcguigan

Fabrizio Pertusati

Original Assignee

Univ College Cardiff Consultants Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-16

Filing date

2013-11-15

Publication date

2019-05-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3235824(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-16 Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en

2013-04-23 Priority claimed from GB201307314A external-priority patent/GB201307314D0/en

2013-11-15 Application filed by Univ College Cardiff Consultants Ltd filed Critical Univ College Cardiff Consultants Ltd

2019-05-20 Application granted granted Critical

2019-05-20 Publication of DK3235824T3 publication Critical patent/DK3235824T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
- H01S5/00—Semiconductor lasers
- H01S5/30—Structure or shape of the active region; Materials used for the active region
- H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
- H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
- H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nanotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Materials Engineering (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catalysts (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)

DK17169878.0T 2012-11-16 2013-11-15 Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat DK3235824T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1220666.0A GB201220666D0 (en)	2012-11-16	2012-11-16	Process for preparing chemical compounds
GB201307314A GB201307314D0 (en)	2013-04-23	2013-04-23	Process for preparing chemical compounds
EP16195036.5A EP3150616B1 (en)	2012-11-16	2013-11-15	Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate

Publications (1)

Publication Number	Publication Date
DK3235824T3 true DK3235824T3 (da)	2019-05-20

Family

ID=49622844

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17169878.0T DK3235824T3 (da)	2012-11-16	2013-11-15	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat
DK16195036.5T DK3150616T3 (da)	2012-11-16	2013-11-15	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK16195036.5T DK3150616T3 (da)	2012-11-16	2013-11-15	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat

Country Status (28)

Country	Link
US (3)	US10005810B2 (da)
EP (3)	EP3235824B1 (da)
JP (5)	JP2016506371A (da)
KR (1)	KR20150103669A (da)
CN (2)	CN104903339A (da)
AU (1)	AU2013346515B2 (da)
CA (1)	CA2891266C (da)
CL (1)	CL2015001307A1 (da)
CY (2)	CY1119161T1 (da)
DK (2)	DK3235824T3 (da)
EA (1)	EA028871B1 (da)
ES (3)	ES2725491T3 (da)
HR (2)	HRP20170791T1 (da)
HU (2)	HUE033335T2 (da)
IL (1)	IL238792A (da)
IN (1)	IN2015DN04090A (da)
LT (2)	LT3150616T (da)
MX (1)	MX374779B (da)
MY (1)	MY176133A (da)
NZ (1)	NZ708177A (da)
PH (1)	PH12015501090B1 (da)
PL (2)	PL3235824T3 (da)
PT (2)	PT3235824T (da)
RS (2)	RS58849B1 (da)
SG (3)	SG10201510324YA (da)
SI (2)	SI3235824T1 (da)
SM (2)	SMT201700349T1 (da)
WO (1)	WO2014076490A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
PT3235824T (pt) *	2012-11-16	2019-05-30	NuCana plc	Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
MX2016006919A (es) *	2013-11-27	2016-08-17	Idenix Pharmaceuticals Llc	Nucleotidos para el tratamiento de cancer de higado.
CN105153257B (zh) *	2014-06-12	2019-03-05	正大天晴药业集团股份有限公司	索非布韦的制备方法
EP3757112B1 (en) *	2014-06-25	2023-06-07	Nucana PLC	Gemcitabine prodrugs
AU2015278900B2 (en)	2014-06-25	2019-04-04	NuCana plc	Formulation comprising a gemcitabine-prodrug
CN105254694B (zh) *	2014-07-14	2018-11-27	正大天晴药业集团股份有限公司	氘代核苷衍生物
EP3172218B1 (en)	2014-07-22	2020-10-21	NuCana plc	Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
BR112017001847A2 (pt) *	2014-07-31	2018-02-27	Sandoz Ag	processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii)
US9675632B2 (en)	2014-08-26	2017-06-13	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
CN105461774B (zh) *	2014-09-30	2020-11-24	江苏豪森药业集团有限公司	索非布韦的制备方法
CN105461773B (zh) *	2014-09-30	2020-12-01	江苏豪森药业集团有限公司	索非布韦的制备方法及其中间体
GB201417644D0 (en) *	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
US9718851B2 (en)	2014-11-06	2017-08-01	Enanta Pharmaceuticals, Inc.	Deuterated nucleoside/tide derivatives
US9732110B2 (en)	2014-12-05	2017-08-15	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
AU2016229966B2 (en) *	2015-03-06	2018-09-27	Atea Pharmaceuticals, Inc.	Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en)	2015-03-26	2019-09-10	Quimica Sintetica, S.A.	Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) *	2015-07-28	2021-05-11	广东东阳光药业有限公司	一种改良的索菲布韦制备方法
CN106543220A (zh)	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	核苷氨基磷酸酯类前药的制备方法及其中间体
CN106478753A (zh) *	2015-09-16	2017-03-08	博瑞生物医药（苏州）股份有限公司	一种nuc‑1031单一异构体的制备方法和用途
WO2017060661A1 (en) *	2015-10-05	2017-04-13	Nucana Biomed Limited	Combination therapy
WO2017090264A1 (ja) *	2015-11-27	2017-06-01	大原薬品工業株式会社	５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
HRP20211812T1 (hr) *	2015-12-11	2022-03-04	NuCana plc	Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522771D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
GB201609602D0 (en) *	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Chemical compounds
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en)	2016-07-14	2018-01-18	Atea Pharmaceuticals, Inc.	Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) *	2016-07-20	2019-03-26	Optimus Drugs (P) Limited	Process for the preparation of sofosbuvir
CN107652342A (zh) *	2016-07-23	2018-02-02	江苏万高药业股份有限公司	核苷氨基磷酸酯类前药的多晶型及其制备方法
ES2907874T3 (es)	2016-09-07	2022-04-26	Atea Pharmaceuticals Inc	Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
US10266558B2 (en) *	2016-10-07	2019-04-23	Alexandre Vasilievich Ivachtchenko	Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CA3041423A1 (en) *	2016-12-23	2018-06-28	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Nucleoside phosphate compound and preparation method and use thereof
JP7066728B2 (ja)	2017-02-01	2022-05-13	アテアファーマシューティカルズ，インコーポレイテッド	Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
WO2019200005A1 (en)	2018-04-10	2019-10-17	Atea Pharmaceuticals, Inc.	Treatment of hcv infected patients with cirrhosis
CN111989335B (zh)	2018-06-12	2023-06-13	四川科伦博泰生物医药股份有限公司	膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
RU2740058C1 (ru) *	2020-06-26	2020-12-31	Общество С Ограниченной Ответственностью "Технология Лекарств"	Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) *	2020-12-07	2023-04-21	武汉伯瑞恒医药科技有限公司	阿糖胞苷结构类似物及其制备方法和用途
JP2024525164A (ja)	2021-06-17	2024-07-10	アテアファーマシューティカルズ，インコーポレイテッド	有利な抗ｈｃｖ併用療法
CN113549076B (zh) *	2021-07-23	2022-12-06	中国药科大学	一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) *	2022-11-15	2024-05-23	Rome Therapeutics, Inc.	Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US6346627B1 (en)	1990-02-01	2002-02-12	Emory University	Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
JP2002500880A (ja)	1998-01-23	2002-01-15	ニューバイオティックスインコーポレイテッド	酵素に触媒される治療剤
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
JP2005522443A (ja)	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
AU2003291726A1 (en)	2002-11-04	2004-06-07	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) *	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
WO2007020193A2 (en) *	2005-08-15	2007-02-22	F. Hoffmann-La Roche Ag	Antiviral phosphoramidates of 4 ' -substituted pronucleotides
GB0623493D0 (en) *	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
US7964580B2 (en) *	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) *	2008-12-08	2010-07-27	Medivir Ab	Nucleótidos uracil ciclopropílicos
BRPI1004575A2 (pt) *	2009-01-09	2016-04-05	Inhibitex Inc	composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
UY33310A (es) *	2010-03-31	2011-10-31	Pharmasset Inc	Sintesis estereoselectiva de activos que contienen fosforo
US9090642B2 (en) *	2010-07-19	2015-07-28	Gilead Sciences, Inc.	Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG188497A1 (en) *	2010-09-22	2013-05-31	Alios Biopharma Inc	Substituted nucleotide analogs
US8772474B2 (en) *	2010-12-22	2014-07-08	Alios Biopharma, Inc.	Cyclic nucleotide analogs
MX339822B (es) *	2011-03-01	2016-06-13	Nucana Biomed Ltd	Derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento contra el cancer.
BR112013022391A2 (pt) *	2011-03-02	2018-01-16	SCHENTAG Jerome	composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
KR20140103914A (ko) *	2011-10-14	2014-08-27	에스티씨. 유엔엠	운반물 경피 전달을 포함하는 타켓 전달용 다공성 나노입자-지지 지질 이중층(프로토셀) 및 그 방법
PT3235824T (pt) *	2012-11-16	2019-05-30	NuCana plc	Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
HK1224229A1 (zh) *	2013-06-26	2017-08-18	Alios Biopharma, Inc.	取代的核苷，核苷酸及其类似物
PL3043803T3 (pl)	2013-09-11	2022-11-07	Emory University	Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
KR102314960B1 (ko) *	2013-10-11	2021-10-19	얀센 바이오파마, 인코퍼레이트.	치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
MX2016006919A (es)	2013-11-27	2016-08-17	Idenix Pharmaceuticals Llc	Nucleotidos para el tratamiento de cancer de higado.
JP2016538306A (ja) *	2013-11-27	2016-12-08	アメリカ合衆国	複素環化合物及びその使用方法
EP3757112B1 (en)	2014-06-25	2023-06-07	Nucana PLC	Gemcitabine prodrugs
AU2015278900B2 (en)	2014-06-25	2019-04-04	NuCana plc	Formulation comprising a gemcitabine-prodrug
EP3172218B1 (en)	2014-07-22	2020-10-21	NuCana plc	Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en)	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
WO2016181093A1 (en)	2015-05-14	2016-11-17	Nucana Biomed Limited	Cancer treatments
WO2017060661A1 (en)	2015-10-05	2017-04-13	Nucana Biomed Limited	Combination therapy
HRP20211812T1 (hr)	2015-12-11	2022-03-04	NuCana plc	Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
DK3393478T3 (da)	2015-12-23	2020-03-23	NuCana plc	Kombinationsterapi
GB201522771D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
CA3008769A1 (en)	2015-12-23	2017-06-29	NuCana plc	Combination therapy comprising nuc-1031 and cisplatin
GB201713914D0 (en)	2017-08-30	2017-10-11	Nucana Biomed Ltd	Combination therapy
JP2020171815A (ja) *	2020-07-29	2020-10-22	株式会社ユニバーサルエンターテインメント	プログラム

2013
- 2013-11-15 PT PT17169878T patent/PT3235824T/pt unknown
- 2013-11-15 HU HUE16195036A patent/HUE033335T2/en unknown
- 2013-11-15 SG SG10201510324YA patent/SG10201510324YA/en unknown
- 2013-11-15 AU AU2013346515A patent/AU2013346515B2/en not_active Ceased
- 2013-11-15 CA CA2891266A patent/CA2891266C/en active Active
- 2013-11-15 HU HUE17169878 patent/HUE044605T2/hu unknown
- 2013-11-15 NZ NZ708177A patent/NZ708177A/en not_active IP Right Cessation
- 2013-11-15 EA EA201590955A patent/EA028871B1/ru unknown
- 2013-11-15 LT LTEP16195036.5T patent/LT3150616T/lt unknown
- 2013-11-15 MX MX2015006195A patent/MX374779B/es active IP Right Grant
- 2013-11-15 CN CN201380069952.2A patent/CN104903339A/zh active Pending
- 2013-11-15 WO PCT/GB2013/053018 patent/WO2014076490A1/en not_active Ceased
- 2013-11-15 SM SM20170349T patent/SMT201700349T1/it unknown
- 2013-11-15 IN IN4090DEN2015 patent/IN2015DN04090A/en unknown
- 2013-11-15 RS RS20190549A patent/RS58849B1/sr unknown
- 2013-11-15 SI SI201331437T patent/SI3235824T1/sl unknown
- 2013-11-15 CN CN202010526209.7A patent/CN111592577A/zh active Pending
- 2013-11-15 EP EP17169878.0A patent/EP3235824B1/en active Active
- 2013-11-15 PL PL17169878T patent/PL3235824T3/pl unknown
- 2013-11-15 SG SG10201510322UA patent/SG10201510322UA/en unknown
- 2013-11-15 SG SG11201503750YA patent/SG11201503750YA/en unknown
- 2013-11-15 JP JP2015542357A patent/JP2016506371A/ja active Pending
- 2013-11-15 ES ES17169878T patent/ES2725491T3/es active Active
- 2013-11-15 EP EP13792965.9A patent/EP2920192B1/en not_active Not-in-force
- 2013-11-15 ES ES13792965.9T patent/ES2618732T3/es active Active
- 2013-11-15 LT LTEP17169878.0T patent/LT3235824T/lt unknown
- 2013-11-15 EP EP16195036.5A patent/EP3150616B1/en active Active
- 2013-11-15 MY MYPI2015001314A patent/MY176133A/en unknown
- 2013-11-15 US US14/442,987 patent/US10005810B2/en active Active
- 2013-11-15 DK DK17169878.0T patent/DK3235824T3/da active
- 2013-11-15 PT PT161950365T patent/PT3150616T/pt unknown
- 2013-11-15 PL PL16195036T patent/PL3150616T3/pl unknown
- 2013-11-15 SM SM20190341T patent/SMT201900341T1/it unknown
- 2013-11-15 DK DK16195036.5T patent/DK3150616T3/da active
- 2013-11-15 ES ES16195036.5T patent/ES2627195T3/es active Active
- 2013-11-15 RS RS20170506A patent/RS56038B1/sr unknown
- 2013-11-15 KR KR1020157015861A patent/KR20150103669A/ko not_active Ceased
- 2013-11-15 SI SI201330652T patent/SI3150616T1/sl unknown
2015
- 2015-05-13 IL IL238792A patent/IL238792A/en active IP Right Grant
- 2015-05-14 CL CL2015001307A patent/CL2015001307A1/es unknown
- 2015-05-15 PH PH12015501090A patent/PH12015501090B1/en unknown
2017
- 2017-05-24 CY CY20171100539T patent/CY1119161T1/el unknown
- 2017-05-29 HR HRP20170791TT patent/HRP20170791T1/hr unknown
- 2017-08-10 JP JP2017154931A patent/JP2018009000A/ja not_active Withdrawn
2018
- 2018-05-31 US US15/994,378 patent/US11040997B2/en active Active
2019
- 2019-05-06 HR HRP20190831TT patent/HRP20190831T1/hr unknown
- 2019-05-09 CY CY20191100503T patent/CY1121663T1/el unknown
- 2019-06-18 JP JP2019112739A patent/JP2019196360A/ja active Pending
2020
- 2020-10-12 JP JP2020171815A patent/JP7519259B2/ja active Active
2021
- 2021-05-18 US US17/323,367 patent/US20220033433A1/en not_active Abandoned
2023
- 2023-01-20 JP JP2023007007A patent/JP2023052536A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
LT3235824T (lt)	2019-07-10
EP3235824B1 (en)	2019-03-27
HK1210784A1 (en)	2016-05-06
AU2013346515A1 (en)	2015-06-04
JP7519259B2 (ja)	2024-07-19
PH12015501090A1 (en)	2015-07-27
KR20150103669A (ko)	2015-09-11
HRP20190831T1 (hr)	2019-08-23
US20180273575A1 (en)	2018-09-27
CN111592577A (zh)	2020-08-28
US20150291650A1 (en)	2015-10-15
JP2019196360A (ja)	2019-11-14
LT3150616T (lt)	2017-07-25
CA2891266A1 (en)	2014-05-22
ES2618732T3 (es)	2017-06-22
EA201590955A1 (ru)	2015-08-31
MY176133A (en)	2020-07-24
PL3235824T3 (pl)	2019-09-30
PH12015501090B1 (en)	2019-01-30
ES2725491T3 (es)	2019-09-24
JP2023052536A (ja)	2023-04-11
JP2021020919A (ja)	2021-02-18
SI3150616T1 (sl)	2017-08-31
PT3150616T (pt)	2017-06-09
JP2018009000A (ja)	2018-01-18
PT3235824T (pt)	2019-05-30
SMT201700349T1 (it)	2017-09-07
JP2016506371A (ja)	2016-03-03
US11040997B2 (en)	2021-06-22
US20220033433A1 (en)	2022-02-03
CY1119161T1 (el)	2018-02-14
EP2920192A1 (en)	2015-09-23
HUE044605T2 (hu)	2019-11-28
HRP20170791T1 (hr)	2017-08-25
IL238792A0 (en)	2015-06-30
PL3150616T3 (pl)	2017-09-29
CN104903339A (zh)	2015-09-09
HUE033335T2 (en)	2017-11-28
EA028871B1 (ru)	2018-01-31
CY1121663T1 (el)	2020-07-31
CL2015001307A1 (es)	2015-12-11
RS56038B1 (sr)	2017-09-29
EP3235824A1 (en)	2017-10-25
SG10201510324YA (en)	2016-01-28
MX2015006195A (es)	2015-12-08
US10005810B2 (en)	2018-06-26
SG11201503750YA (en)	2015-06-29
IN2015DN04090A (da)	2015-10-09
ES2627195T3 (es)	2017-07-27
WO2014076490A1 (en)	2014-05-22
NZ708177A (en)	2017-08-25
EP3150616B1 (en)	2017-05-10
MX374779B (es)	2025-03-06
CA2891266C (en)	2020-12-08
EP2920192B1 (en)	2017-02-22
SMT201900341T1 (it)	2019-07-11
SG10201510322UA (en)	2016-01-28
EP3150616A1 (en)	2017-04-05
BR112015011155A2 (pt)	2017-07-11
AU2013346515B2 (en)	2017-05-25
IL238792A (en)	2017-09-28
SI3235824T1 (sl)	2019-08-30
RS58849B1 (sr)	2019-07-31
DK3150616T3 (da)	2017-06-06

Publication	Publication Date	Title
DK3235824T3 (da)	2019-05-20	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat
DK2906696T4 (da)	2023-02-27	Fremgangsmåder til modulering af c9orf72-ekspression
DK3533792T3 (da)	2021-06-28	Krystallinske former af en androgenreceptormodulator
DK2845905T3 (da)	2021-06-14	Fremstilling af oligosaccharider
EP2850106A4 (en)	2016-04-20	BISPECIFIC SCFV IMMUNOFUSION (BIF)
BR302012005260S1 (pt)	2013-10-08	Configuracao aplicada em autoinjetor
BR302012005258S1 (pt)	2013-10-08	Configuracao aplicada em autoinjetor
DK3281664T3 (da)	2021-01-25	Nasale indgivelsesindretninger
EP2979402A4 (en)	2016-11-30	FORWARDING OF PACKAGES
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
BR302012005259S1 (pt)	2013-10-08	Configuracao aplicada em autoinjetor
DK3461895T3 (da)	2020-07-20	Modulation af ube3a-ats-ekspression
HUE042443T2 (hu)	2019-06-28	GPR6 tetrahidropiridopirazin-modulátorai
EP2880905A4 (en)	2015-12-23	AVAILABILITY OF COMMUNICATION MODES
EP2803885A4 (en)	2015-11-11	MIXER
EP2873453A4 (en)	2016-03-23	STIRRERS
SMT201600410B (it)	2017-01-10	Modulatori diidropirazolici di gpr40
PT2953948T (pt)	2017-12-12	Antagonistas de integrina fluorada
DK2965026T3 (da)	2019-10-28	Generering af slushice
DK2822568T3 (da)	2020-08-10	Anvendelser af caseinsammensætninger
DK2894998T3 (da)	2020-03-02	Rotation af kegle
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
DK2854831T3 (da)	2024-10-14	Fremstilling af degarelix
EP3012307A4 (en)	2016-06-29	MIXED REFRIGERANT
HUE049492T2 (hu)	2020-09-28	Magéleterõ modulálása